Mindfulness training does not reduce generalized hyperalgesia in chronic tension-type headache

Journal of Pain Management

Volumn 6, Issue 3, 2013, Pages 217-221

  Cathcart, Stuart ^a   Barone, Vanessa ^a   Immink, Maarten ^b   Proeve, Michael ^c  

^a UNIVERSITY OF CANBERRA   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Headache; Mindfulness; Pain sensitivity; Randomized controlled trial

Indexed keywords

EID: 84892471658     PISSN: 19395914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Ballantyne JC, Mao J. Opioid therapy for chronic pain. New Engl J Med 2003;349(20):1943-53.
2. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: Molecular mechanisms and clinical considerations. Clin Journal Pain 2008;24(6):479-96.
3. Mao J, Price DD, Mayer DJ. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase. C J Neurosci 1994;14(4):2301-12.
4. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 1995;62(3): 259-74.
5. Compton MA. Cold-pressor pain tolerance in opiate and cocaine abusers: correlates of drug type and use status. J Pain Symptom Manage 1994;9(7):462-73.
6. Lynch SS, Cheng CM, Yee JL. Intrathecal ziconotide for refractory chronic pain. Ann Pharmacother 2006;40(7- 8):1293-1300.
7. AzurPharma. Prialt package insert. 2010; Accessed 2011 Jul 28.URL: http://www.azurpharma.com/pdf/prialt/PRLTp-10-01-R6%20Cropped%20for%20Web.pdf.
8. Schmidtko A, et al. Ziconotide for treatment of severe chronic pain. Lancet 2010;375(9725):1569-77.
9. Perret D, Luo ZD. Targeting voltage-gated calcium channels for neuropathic pain management. Neurotherapeutics 2009;6(4):679-92.
10. Deer T, et al. Polyanalgesic consensus conference 2007; Recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2007;10(4):300-28.
11. Wallace MS. Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain. Expert Rev Neurother 2006;6(10):1423-8.
12. Bowersox SS, Luther R. Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus. Toxicon 1998;36(11): 1651-8.
13. Vanegas H, Schaible H. Effects of antagonists to highthreshold calcium channels upon spinal mechanisms of pain, hyperalgesia and allodynia. Pain 2000;85(1-2):9-18.
14. Kapural L, et al. Intrathecal ziconotide for complex regional pain syndrome: Seven Case Reports. Pain Pract 2009;9(4):296-303.
15. Chaplan SR, Pogrel JW, Yaksh TL. Role of voltagedependent calcium channel subtypes in experimental tactile allodynia. J Pharmacol Exp Ther 1994;269(3):1117-23.
16. Burton AW, et al. Considerations and methodology for trialing ziconotide. Pain Physician 2010;13(1):23-33.
17. Madigan Army Medical Center, Clinical practice guidelines: provider tools 2010. Accessed 2011 Jul 10. URL http://www.mamc.amedd.army.mil/clinical/standards/pain_pro.htm
18. Partners against pain, Pain treatment topics, pain and disability assessment tools 2010. Accessed 2011 Jul 12. URL:http://www.mamc.amedd.army.mil/clinical/standard s/pain_pro.htm
19. Yassen A, et al. Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine. Clin Pharmacokinet 2007;46(5):433-47.
20. Cowan A, Lewis JW, Macfarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 1977;60(4):537-45.